$ News

Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting

Affimed to Present at the Leerink Partners Global Healthcare Conference 2025

Affimed Shares Fall 32% on Clinical Update

Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients

AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy

FDA ARMAT status for Affimed and Artiva’s lymphoma combo therapy

Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)

Is Affimed N.V. (AFMD) the Best German Stock to Buy Now?

Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ...

Affimed N.V. (AFMD) Q3 2024 Earnings Call Transcript

Affimed N.V.: Q3 Earnings Snapshot

Affimed Reports Third Quarter 2024 Financial Results & Business Update

Affimed N.V. 2024 Q3 - Results - Earnings Call Presentation

Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024

Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates

Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma

683 Capital Management, LLC Expands Stake in Affimed NV